Low-dose Combination of Three Antihypertensive Drugs
Phase 4
- Conditions
- Arterial Hypertension
- Interventions
- Drug: Tripliam (perindopril, indapamide, amlodipine)Drug: Reaptan (perindopril, amlodipine)
- Registration Number
- NCT02710552
- Lead Sponsor
- University of Roma La Sapienza
- Brief Summary
The aim of the study is to compare the efficacy and safety of low-dose combination of three antihypertensive drugs versus fixed high-dose combination of two antihypertensive drugs in arterial hypertension
- Detailed Description
The aim of the study is to compare the efficacy and safety of commercially available low-dose combination of three antihypertensive drugs versus commercially available fixed high-dose combination of two antihypertensive drugs in arterial hypertension
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with arterial hypertension resistant to monotherapy
Exclusion Criteria
None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Three antihypertensive Drugs Tripliam (perindopril, indapamide, amlodipine) Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine Two antihypertensive drugs Reaptan (perindopril, amlodipine) Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
- Primary Outcome Measures
Name Time Method Number of patients who reach target blood pressure From baseline to the end of the 3-month study period How many patients have blood pressure within normal limits
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sapienza University
🇮🇹Rome, Italy